Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling

doi:10.1016/j.canlet.2016.08.020

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 药理学第三研究室

	Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling
	Chen, Huanjun 1,2,3; Cong, Qifei 1,2,3; Du, Zhenyun 1,2,3; Liao, Wenfeng 1,2,3; Zhang, Lei 1,2,3; Yao, Yanli 1,2,3; Ding, Kan1,2,3
刊名	CANCER LETTERS
	2016-11-01
卷号	382 期号:1 页码:44-52
关键词	Fucoidan Angiogenesis VEGF Lung cancer
ISSN号	0304-3835
DOI	10.1016/j.canlet.2016.08.020
文献子类	Article
英文摘要	Fucoidan may inhibit angiogenesis. However, its functional target molecule and the underlying mechanism are still vague. In the present study, we showed that sulfated fucoidan FP08S2 from Sargassum fusiforme inhibited tube formation as well as migration and invasion of human microvascular endothelial cells (HMEC-1). In addition, FP08S2 was confirmed to disrupt VEGF-induced angiogenesis both in vitro and in vivo. Further study indicated that FP08S2 could bind to both VEGF and VEGFR2 to interfere with VEGF-VEGFR2 interaction. Moreover, VEGFR2/Erk/VEGF signaling pathway was blocked by FP08S2 in HMEC-1 cells. Importantly, FP08S2 impeded the growth and microvessel formation of A549 cancer cell xenograft in nude mice. These results suggested that FP08S2 presented remarkable anti-angiogenic activity via blocking VEGF signaling and could be a potential novel leading compound to inhibit lung cancer cell growth. (C) 2016 Published by Elsevier Ireland Ltd.
资助项目	National Natural Science Foundation of China (NSFC) in China[31230022] ; Shanghai Foundation for Outstanding Academic Leaders in China[16XD1404500]
WOS关键词	HYPOXIA-INDUCIBLE FACTOR-1 ; TUMOR ANGIOGENESIS ; THERAPEUTIC IMPLICATIONS ; BROWN SEAWEEDS ; VEGF ; MECHANISMS ; RECEPTOR ; MICROENVIRONMENT ; TRANSDUCTION ; EXPRESSION
WOS研究方向	Oncology
语种	英语
出版者	ELSEVIER IRELAND LTD
WOS记录号	WOS:000386985800005
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/275839]
专题	药理学第三研究室
通讯作者	Ding, Kan
作者单位	1.Chinese Acad Sci, Shanghai Inst Mat Med, Glycochem & Glycobiol Lab, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China; 2.Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Key Lab Receptor Res, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China;
推荐引用方式 GB/T 7714	Chen, Huanjun,Cong, Qifei,Du, Zhenyun,et al. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling[J]. CANCER LETTERS,2016,382(1):44-52.
APA	Chen, Huanjun.,Cong, Qifei.,Du, Zhenyun.,Liao, Wenfeng.,Zhang, Lei.,...&Ding, Kan.(2016).Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.CANCER LETTERS,382(1),44-52.
MLA	Chen, Huanjun,et al."Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling".CANCER LETTERS 382.1(2016):44-52.